Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (51-60 of 310) with videos related to

Pageof 31
Sort By:
Harefuah|October 24, 2021
[NATIONAL DIABETES PROGRAM IN ISRAEL AND IN SELECTED COUNTRIES - CURRENT STATE AND FUTURE TRENDS]Orly Tamir, Maya Skudowitz, Itamar Raz
Diabetes/Metabolism Research and Reviews|October 12, 2010
Prevention of type 1 diabetes: today and tomorrowSimona Cernea, Minodora Dobreanu, Itamar Raz
Journal of Diabetes|September 6, 2017
Digital health technology and diabetes managementAvivit Cahn, Amit Akirov, Itamar Raz
Expert Opinion on Drug Safety|March 1, 2016
Saxagliptin for the treatment of diabetes - a focus on safetySimona Cernea, Avivit Cahn, Itamar Raz
Journal of Diabetes|November 23, 2019
SGLT2 inhibitors for primary prevention of cardiovascular eventsItamar Raz, Simona Cernea, Avivit Cahn
Annals of Translational Medicine|February 5, 2020
The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?Avivit Cahn, Simona Cernea, Itamar Raz
Drugs|December 8, 2007
The role of sulodexide in the treatment of diabetic nephropathyRam Weiss, Robert Niecestro, Itamar Raz
Expert Review of Clinical Pharmacology|March 10, 2017
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetesSimona Cernea, Avivit Cahn, Itamar Raz
Cardiovascular Diabetology|August 24, 2018
Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular diseaseNaim Shehadeh, Itamar Raz, Afif Nakhleh
Reviews in Endocrine & Metabolic Disorders|April 24, 2016
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Pageof 31

Showing results (51-60 of 310) with videos related to

Sort By:
Pageof 31
Harefuah|October 24, 2021
[NATIONAL DIABETES PROGRAM IN ISRAEL AND IN SELECTED COUNTRIES - CURRENT STATE AND FUTURE TRENDS]Orly Tamir, Maya Skudowitz, Itamar Raz
Diabetes/Metabolism Research and Reviews|October 12, 2010
Prevention of type 1 diabetes: today and tomorrowSimona Cernea, Minodora Dobreanu, Itamar Raz
Journal of Diabetes|September 6, 2017
Digital health technology and diabetes managementAvivit Cahn, Amit Akirov, Itamar Raz
Expert Opinion on Drug Safety|March 1, 2016
Saxagliptin for the treatment of diabetes - a focus on safetySimona Cernea, Avivit Cahn, Itamar Raz
Journal of Diabetes|November 23, 2019
SGLT2 inhibitors for primary prevention of cardiovascular eventsItamar Raz, Simona Cernea, Avivit Cahn
Annals of Translational Medicine|February 5, 2020
The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?Avivit Cahn, Simona Cernea, Itamar Raz
Drugs|December 8, 2007
The role of sulodexide in the treatment of diabetic nephropathyRam Weiss, Robert Niecestro, Itamar Raz
Expert Review of Clinical Pharmacology|March 10, 2017
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetesSimona Cernea, Avivit Cahn, Itamar Raz
Cardiovascular Diabetology|August 24, 2018
Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular diseaseNaim Shehadeh, Itamar Raz, Afif Nakhleh
Reviews in Endocrine & Metabolic Disorders|April 24, 2016
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Pageof 31